ArticlePloS one2026

Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS.

Yu Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.